[ad_1]
Long Beach, California, July 8, 2021 /PRNewswire/ – Anivive, a pet health technology company that changes the process of treatment discovery and development, received 500,000 USD Continue to study the use of LAVERDIA™ -CA1 (verdinexor) in the treatment of canine lymphoma in the grant funding.
The grant comes from the U.S. Food and Drug Administration as part of the agency’s secondary use/minor species program, which aims to support new animal drugs for the treatment of uncommon or under-treated diseases such as canine lymphoma . Anivive was one of four companies selected to receive the grant.
Anivive Chief Medical Officer said: “We are honored to be the recipient of the FDA grant.” David Bruyett, DVM, DACVIM. “These funds will help cover some related costs…
The full story on Benzinga.com
[ad_2]
Source link
